Sarepta Therapeutics, Inc. (SRPT) — Fair Value Analysis

Base-case fair value (P50): $21.21 · Current price: $17.71 · Verdict: Undervalued

The Verdict on SRPT

Based on our Monte Carlo simulations, SAREPTA THERAPEUTICS INC (SRPT) is currently Fairly Valued. The analysis indicates a median fair value (P50) of $21.21, compared to its current trading price of $17.71. This suggests a potential +19.8% relative to the current market price, implying the stock is not significantly overvalued or undervalued by our models at this juncture. While there's a positive lean, the "Fairly Valued" verdict reflects that the market's pricing is largely in line with our statistical projections, accounting for future uncertainty across thousands of forward scenarios.

How SRPT stacks up against peers

SRPT holds an average quality tier, reflecting its operational and financial health when benchmarked against its sector. This average positioning suggests a balanced risk-reward profile, where the company's fundamentals are neither a standout strength nor a significant weakness compared to its industry counterparts. Despite the +19.8% potential from $17.71 to our $21.21 fair value, an average quality tier typically means investors should anticipate a moderate risk exposure consistent with the broader sector dynamics.

What this means for investors

For investors considering SRPT, the "Fairly Valued" assessment, alongside an average quality tier, signals a stock priced near its intrinsic value according to our Monte Carlo models. The indicated +19.8% from the current $17.71 to the $21.21 fair value suggests some room for appreciation, but not a deep discount. FairCurve users can access the full probabilistic distribution, including bear and bull case targets, to contextualize this +19.8% within a wider range of potential outcomes. Sign up for FairCurve to see the full bear/bull distribution and track SRPT's fair value as new fundamentals are released.